

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

**0 240 131**  
**A2**

(12)

**EUROPEAN PATENT APPLICATION**

(21) Application number: 87301522.6

(51) Int. Cl.<sup>3</sup>: **A 61 K 31/135**  
**A 61 K 31/205**

(22) Date of filing: 23.02.87

(30) Priority: 24.02.86 GB 8604528

(43) Date of publication of application:  
07.10.87 Bulletin 87/41(84) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE(71) Applicant: IMPERIAL CHEMICAL INDUSTRIES PLC  
Imperial Chemical House Millbank  
London SW1P 3JF(GB)(72) Inventor: Kraus, Hans Alfred  
Im Gänswasen 4  
D-7050 Walblingen-Neustadt(DE)(74) Representative: Smith, Stephen Collyer et al,  
Imperial Chemical Industries PLC Legal Department:  
Patents Po Box 6 Bessemer Road  
Welwyn Garden City Herts, AL7 1HD(GB)

(54) Tamoxifen for topical use.

(57) The invention concerns a new therapeutic agent for use  
in treating psoriasis, new compositions of the therapeutic  
agent for topical administration and a new method of  
treating psoriasis.

**EP 0 240 131 A2**

TITLE MODIFIED  
see front page

THERAPEUTIC AGENTS

This invention relates to a therapeutic agents for use in a new method of medical treatment and, more particularly, it relates to an agent for use in a new method for the treatment of psoriasis and to topical formulations of said agent.

Psoriasis is a common chronic inflammatory disease of the skin and in some cases, also the joints, which affects virtually all ages and which is difficult to treat successfully. The aetiology of psoriasis is largely unknown and the objective of most treatment is to suppress the abnormally rapid skin cell turnover process rather than to effect a cure. Topical treatments such as dithranol and coal tar derivatives, with or without UV irradiation, have some effect in controlling mild to moderate psoriasis, but the more severe cases require systemic treatment with cytotoxic agents such as methotrexate which have overt adverse side effects. Present treatments of psoriasis have been reviewed by R.H. Champion (British Medical Journal, 1986; 292, 1693). There is thus a need for a new therapeutic agent which is capable of controlling psoriasis without the production of unwanted side-effects.

It has now been found that administration of tamoxifen (as its citrate salt) results in the remission of psoriasis of long standing without any overt side-effects and this is the basis of the invention.

According to the present invention there is provided a method for the treatment of psoriasis affecting a warm-blooded animal which comprises the administration to said animal of an effective amount of tamoxifen or a pharmaceutically acceptable acid-addition salt thereof.

According to a further feature of the invention there is provided the use of tamoxifen, or of a pharmaceutically acceptable acid addition salt thereof, for the treatment of psoriasis affecting a warm-blooded animal such as man.

According to a yet further feature of the invention there is provided the use of tamoxifen, or of a pharmaceutically acceptable acid-addition salt thereof, for the manufacture of a novel medicament for the treatment of psoriasis affecting a warm-blooded animal such as man.

The chemical compound tamoxifen [(Z)-2-[p-(1,2-diphenylbut-1-enyl)phenoxy]ethyldimethylamine] is known to be especially useful in the treatment of hormone-dependent tumours, and especially in the treatment of breast cancer in women. Comprehensive reviews of its clinical usage are available, for example by Furr and Jordan in "Pharmacology and Therapeutics", 1984, Volume 25, pages 127-205. Tamoxifen also has utility in treating male infertility (Furr and Jordan, above, Section 8.3.1.2, page 185).

A suitable pharmaceutically acceptable acid-addition salt is, for example, the hydrochloride, hydrobromide, citrate or D-gluconate salt. The last salt is particularly suitable for the production of topical formulations of tamoxifen.

It is to be understood that "warm blooded animal" includes both male and female humans.

The tamoxifen or an acid-addition salt thereof (hereafter referred to as "the therapeutic agent") may be administered, for example orally or topically for the relief of psoriasis, and may be used in a conventional oral or topical formulation.

Topical formulations of the therapeutic agent for use in the treatment of psoriasis are novel and are provided as a further feature of the invention and comprise tamoxifen or a pharmaceutically acceptable acid-addition salt thereof (especially a generally water-soluble salt such as the D-gluconate) together with one or more dermatologically acceptable excipients.

A suitable oral formulation, is for example, a tablet or capsule, preferably a tablet containing, for example, 10, 20, 30 or 40 mg. of therapeutic agent. In general, it will be administered at a dose in the range 20 to 80 mg. per day, either as a single dose or as divided doses.

A suitable topical formulation is, for example, an ointment, cream or lotion containing up to 10% by weight of the therapeutic agent and typically in the range, for example 0.1 to 5% by weight. This will normally be applied to the skin of the patient (either to the unaffected or the psoriatic area) once or twice per day. Topical formulations may be obtained by conventional procedures and using dermatologically acceptable excipients, well known in the art.

Examples of dermatologically suitable excipients include those well known in the art of pharmacy for the production of topical formulation, such as arachis oil, non-volatile fatty alcohols, acids and/or esters (e.g. cetostearyl alcohol, cetyl alcohol, stearyl alcohol, stearic acid or cetyl esters wax); volatile alcoholic compounds [e.g. lower alkanols such as ethanol or isopropanol]; glycols and glycol ethers (e.g. propylene glycol or ethyl digol); glycerol and glycerol ethers; emulsifying agents (e.g. sorbitan stearate, sorbitan trioleate, polysorbate 60 or a mixture of polyoxyethylated oleyl or cetyl alcohol); preservatives (e.g. (1-4C)alkyl hydroxybenzoates such as methyl or propyl hydroxybenzoates); and non-volatile hydrocarbons such as soft paraffin or liquid paraffin. Examples of suitable formulations are provided in the accompanying Examples.

An agent to improve penetration through the skin, for example dimethyl sulphoxide, N-methyl-2-pyrrolidinone or 1-dodecylazacycloheptan-2-one, may also conveniently be present in a topical formulation.

A particular ointment formulation may be prepared, for example, by dispersing the therapeutic agent as defined above in a suitable organic diluent, for example soft paraffin, optionally in the presence of an emulsifying and/or thickening agent, for example sorbitan monostearate.

A particular emulsion formulation such as a cream or lotion may be obtained for example, by adding a slurry of tamoxifen free base in ethanol or 2-propanol to an aqueous solution of D-gluconic acid to form tamoxifen gluconate in situ, which mixture is then combined with the required components of the disperse phase.

The topical formulations are conveniently provided for the treatment of psoriasis packaged in dispensers such as deformable tubes containing for example, 15 to 200 g of formulation and such filled dispensers are provided as a further feature of the invention.

One preferred formulation for oral administration contains tamoxifen citrate together with one or more pharmaceutically acceptable diluents or carrier in the form of a tablet containing 10, 20, 30 or 40 mg of active ingredient, for example, such as is commercially available under the ICI trade mark 'Nolvadex' for use in the treatment of breast cancer.

A preferred formulation for topical administration contains tamoxifen D-gluconate together with one or more dermatologically acceptable excipients in the form of an ointment, cream or lotion. In addition, the therapeutic agent may also be administered topically by spray or aerosol.

The invention is illustrated, but not limited, by the following Examples,-

EXAMPLE 1

5

A white male patient, aged about 33 years, had been afflicted with psoriasis for about 10 years, the worst areas affected being the palms of his hands. All previous attempts to treat this condition had failed. The patient was also  
10 infertile, and treatment for the infertility was attempted by the oral administration of tamoxifen citrate (available under the trade mark 'Nolvadex' from Imperial Chemical Industries PLC) at a dose of 20 mg twice per day. After 2 months of treatment, all symptoms of the psoriasis disappeared. After a  
15 further 3 months, treatment was discontinued and the psoriasis returned 3 weeks later. Treatment with tamoxifen citrate was recommenced and the psoriasis again disappeared, and remained absent as treatment was continued. No untoward effects were observed during the period of treatment.

20

EXAMPLE 2

Clinical responses to oral treatment with tamoxifen citrate have been observed in a number of additional patients. For example a white male patient, aged about 32 years and afflicted with severe psoriasis for several years, showed a  
25 marked reduction in symptoms following administration of tamoxifen citrate orally at 20 mg twice daily. The beneficial effect was lost on withdrawing the therapeutic agent but returned with further treatment. No adverse effects were observed during treatment.

30

EXAMPLE 3 (Components are given in % w/w unless otherwise stated.)

This example describes a number of typical cream formulations for topical use and which contain tamoxifen as its D-gluconate salt.

35

For each formulation, the tamoxifen D-gluconate

salt may be obtained by mixing an ethanolic slurry of tamoxifen as the free base with an aqueous solution of D-gluconic acid, obtained by hydrolysing a 20% w/v solution of D-gluconolactone in water by heating at 70°C for 15 to 30 minutes. [Note, the minimum volume of ethanol is used and 5 ml of the aqueous D-gluconic acid solution is added per 1 g of tamoxifen free base]. Stirring is then continued until a clear solution is obtained. The required volume of this solution is then added to other excipients to produce the following cream formulations in which "active ingredient" is tamoxifen D-gluconate salt:-

#### FORMULATION I

	Active ingredient	0.5-2.5
15	Cetostearyl alcohol	4.0
	Cetyl esters wax	2.0
	(synthetic spermaceti)	
	Arachis oil	5.0
	* 'Brij' 72 (steareth 2)	2.5
20	** 'Brij' 78 (steareth 20)	1.5
	Methyl hydroxybenzoate	0.15
	Propyl hydroxybenzoate	0.08
	Purified water	to 100%
25	* polyethylene glycol ether of stearyl alcohol containing an average of 2 oxyethyl groups per molecule ['Brij' is a trade mark].	
30	** polyethylene glycol ether of stearyl alcohol containing an average of 20 oxyethyl groups per molecule.	

FORMULATION II

	Active ingredient	0.5-2.5
	Cetostearyl alcohol	5.0
5	Cetyl esters wax	3.0
	(synthetic spermaceti)	
	Liquid paraffin	3.0
	Glyceryl stearate SE	
	(Self emulsifying grade)	3.0
10	'Brij' 78	1.0
	(Steareth 20)	
	Methyl hydroxybenzoate	0.15
	Propyl hydroxybenzoate	0.08
	Butylated hydroxytoluene	0.05
15	Purified water	to 100%

FORMULATION III

	Active ingredient	0.5-2.5
20	*'Arlatone' 983S	4.0
	Cetyl alcohol	2.5
	Stearic acid	1.5
25	Propylene glycol	2.0
	Glycerin	2.0
	Methyl hydroxybenzoate	0.15
	Propyl hydroxybenzoate	0.08

30 \* Polyethylene glycol ether derivative (containing an average of 5 oxyethyl units per molecule) of glyceryl stearate  
 ['Arlatone' is a trade mark].



FORMULATION IV

	Active ingredient	0.5-2.5
	Cetostearyl alcohol	1.0
5	Stearic acid	1.5
	*"Arlamol" E	9.0
	(PPG 15 stearyl ether)	3.0
	'Brij' 72	3.0
	(steareth 2)	
10	**'Brij' 721	2.0
	(steareth 21)	
	Propylene glycol	4.0
	Methyl hydroxybenzoate	0.15
	Propyl hydroxybenzoate	0.08
15	Purified water to 100%	

\* polypropylene glycol ether of stearyl alcohol containing an average of 15 2-oxypropyl groups per molecule.

20 \*\* polyethylene glycol ether of stearyl alcohol containing an average of 21 oxyethyl groups per molecule.

['Arlamol' is a trade mark]

25 FORMULATION V

	Active ingredient	0.5-2.5%
	Cetostearyl alcohol	5.0
	Cetyl esters wax	2.0
30	(synthetic spermaceti)	2.0
	'Span' 60	2.0
	(sorbitan stearate)	
	'Tween' 60	2.0
	(polysorbate 60)	
35	Glycerol	1.0

Methyl hydroxybenzoate	0.15
Propyl hydroxybenzoate	0.08
Purified water to	100%

5 ['Span' and 'Tween' are trade marks]

NOTES:

10 (i) The methyl and propyl hydroxybenzoates are present as preservatives and may be replaced by one or more other conventional preservatives.

(ii) The above formulations may optionally contain 0.5 to 5.0% of a penetration enhancer such as dimethyl sulphoxide.

15 (iii) It will be understood that the above formulations will also contain residual ethanol from the initial preparation of the active ingredient.

EXAMPLE 4 (Components are given in % w/w except where indicated)

This Example illustrates an ointment formulation suitable for topical administration:-

20	Active ingredient*	0.5
	Ethyl digol	5.0
	Ethanol 96% B.P.	3.0 w/v
	Purified water	2.0
25	'Span' 85	3.0
	(sorbitan trioleate)	
	White soft paraffin to	100%

30 \*Note: the active ingredient may either be tamoxifen D-gluconate (conveniently prepared in situ in the ethanol/ethyl digol mixture) or tamoxifen citrate.

**EXAMPLE 5** (Components are given in % w/w)

This Example illustrates a further ointment formulation suitable for topical formulation:-

5	Active ingredient *	0.5-2.5
	Light liquid paraffin	5-10
	White soft paraffin	to 100%

10 \* Note: the active ingredient may be, for example, finely micronised tamoxifen citrate or finely powdered tamoxifen D-gluconate (for example such as may be obtained by freeze-drying an aqueous solution of the salt).

CLAIMS

What is claimed is,-

- 5        1.        A pharmaceutical composition adapted for topical use  
which comprises as active ingredient tamoxifen or a  
pharmaceutically acceptable acid-addition salt thereof, together  
with one or more dermatologically acceptable excipients.
- 10       2.        A composition as claimed in claim 1 which is in the  
form of an ointment, cream or lotion.
3.        A composition as claimed in claim 1 or 2 containing up  
to 10% by weight of the active ingredient.
- 15       4.        A composition as claimed in claim 1 or 2 containing  
0.1 to 5% by weight of active ingredient.
5.        A composition as claimed in any of claims 1-4 wherein  
20       the active ingredient is a generally water-soluble salt of  
tamoxifen.
6.        A composition as claimed in any of claims 1-4 wherein  
the active ingredient is tamoxifen D-gluconate.
- 25       7.        A filled dispenser of topically useful pharmaceutical  
composition wherein the composition is as defined in any of claims  
1-6 and is present in an amount of 5 to 200 g.
- 30       8.        A composition as claimed in any of claims 1-6 which  
comprises in addition a skin penetration enhancer.

9. The use of a therapeutic agent selected from tamoxifen and the pharmaceutically acceptable acid-addition salts thereof in the manufacture of a novel medicament for use in the treatment of psoriasis.
- 5 10. A process for the manufacture of a novel medicament for use in the treatment of psoriasis which comprises bringing a therapeutic agent selected from tamoxifen and the pharmaceutically acceptable salts thereof into a form suitable for topical administration by combining said agent with one or more
- 10 dermatologically acceptable carriers.
11. A process as claimed in claim 10 wherein the therapeutic agent is selected from tamoxifen and its D-gluconate and citrate salts.

SC33777EP

SP02

SCS/MJW: 4Feb87

CLAIMS (for the contracting States Greece, Spain and Austria)

What is claimed is:-

1. A process for the manufacture of a novel medicament for use in the treatment of psoriasis which comprises bringing a therapeutic agent selected from tamoxifen and the pharmaceutically acceptable salts thereof into a form suitable for topical administration by combining said agent with one or more dermatologically acceptable carriers.

2. A process as claimed in claim 1 wherein the therapeutic agent is selected from tamoxifen and its D-gluconate and citrate salts.

3. The use of a therapeutic agent selected from tamoxifen and the pharmaceutically acceptable acid-addition salts thereof in the manufacture of a novel medicament for use in the treatment of psoriasis.

SC337770EE

SF02

SCS/MJW: 4Feb87

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

**0 240 131  
A3**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 87301522.6

(61) Int. Cl.<sup>3</sup>: **A 61 K 31/135**  
**A 61 K 31/205**

(22) Date of filing: 23.02.87

(30) Priority: 24.02.86 GB 8604528

(43) Date of publication of application:  
07.10.87 Bulletin 87/41

(88) Date of deferred publication of search report: 15.11.89

(84) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

(71) Applicant: **IMPERIAL CHEMICAL INDUSTRIES PLC**  
Imperial Chemical House Millbank  
London SW1P 3JF(GB)

(72) Inventor: **Kraus, Hans Alfred**  
Im Gänswasen 4  
D-7050 Waiblingen-Neustadt(DE)

(74) Representative: **Smith, Stephen Collyer et al,**  
Imperial Chemical Industries PLC Legal Department:  
Patents Po Box 6 Bessemer Road  
Welwyn Garden City Herts, AL7 1HD(GB)

(54) **Tamoxifen for topical use.**

(57) The invention concerns a new therapeutic agent for use in treating psoriasis, new compositions of the therapeutic agent for topical administration and a new method of treating psoriasis.

**EP 0 240 131 A3**



European Patent  
Office

# EUROPEAN SEARCH REPORT

0240131

Application Number

EP 87 30 1522

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
X	WO-A-8 503 228 (MAUVAIS-JARVIS) * Page 3, lines 1-19; page 4, line 32 - page 5, line 22; claims * ---	1-2	A 61 K 31/135 A 61 K 31/205
A	WO-A-8 401 506 (GATE) * Page 2, line 23 - page 3, line 12; page 5, line 5 * ---	1-8	
A	EUR. J. CANCER CLIN. ONCOL., vol. 21, no. 10, 1985, pages 1171-1174, Pergamon Press Ltd, GB; C. ROSE et al.: "Endocrine treatment with anti-estrogen, antiandrogen or progestagen of advanced malignant melanoma: three consecutive phase II trials" * Abstract; pages 1172-1173, section: "Discussion" * ---	9-11	
A	CANCER TREATMENT REPORTS; vol. 66, no. 6, 1982, page 1447; C.G. LEICHMAN et al.: "Phase II trial of tamoxifen in malignant melanoma" * Whole article * ---	9-11	TECHNICAL FIELDS SEARCHED (Int. Cl.4)  A 61 K
A	EUROP. J. CANCER CLIN. ONCOL., vol. 20, no. 6, 1984, pages 807-815; P.G. GILL et al.: "The effect of tamoxifen on the growth of human malignant melanoma in vitro" * Abstract; page 807, right-hand column, line 21 - page 808, left-hand column, line 11; page 812, right-hand column, line 13 - page 813, left-hand column, line 8; page 813, left-hand column, line 39 - page 813, right-hand column, line 8 * --- -/-	9-11	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 29-08-1989	Examiner GOETZ G.
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document  T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons  & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P0401)





European Patent  
Office

## EUROPEAN SEARCH REPORT

0240131  
Page 2

Application Number

EP 87 30 1522

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
P,A	BRIT. MED. JOURNAL, vol. 292, June 1986, pages 1693-1696; R.H. CHAMPION: "Psoriasis" * Whole document * -----	9-11	
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 29-08-1989	Examiner GOETZ G.
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P0401)

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**